Supplementary information

Label-free blood plasma test based on surface-enhanced Raman scattering for tumor stages detection in nasopharyngeal cancer

Duo Lin, Jianji Pan, Hao Huang, Guannan Chen, Sufang Qiu, Hong Shi, Weiwei Chen, Yun Yu, Shangyuan Feng, Rong Chen

 Table S1.
 Clinical information on nasopharyngeal cancer patients

No.	Age	Sex	T stage	Pathological type	VCA-IgA (s/co)	EA-IgA (s/co)	EBV-DNA (copies/ml)
1	44	male	T1	non cornification undifferentiated carcinoma	4.05	2.02	5.59×10^2
2	65	male	T1	Poorly differentiated squamous cell carcinomas	1.78	0.67	6.21×10^2
3	52	male	T1	non cornification undifferentiated carcinoma	2.96	0.94	
4	45	male	T1	Poorly differentiated squamous cell carcinomas	4.33	0.33	5.79×10^2
5	47	male	T1	non cornification undifferentiated carcinoma	2.43	0.32	3.21×10^3
6	49	male	T1	non cornification undifferentiated carcinoma	4.33	1.79	3.60×10^2
7	75	female	T1	vesicular nucleus cell carcinoma	0.55	0.12	1.15×10^2
8	60	male	T1	non cornification undifferentiated carcinoma	4.33	3.88	
9	35	female	T1	squamous cell carcinomas	6.07	1.5	1.29×10^3
10	49	male	T1	non cornification undifferentiated carcinoma	1.16	0.25	<5.0×10^2
11	48	male	T1	non cornification undifferentiated carcinoma	2.09	0.19	2.53×10^2
12	46	female	T1	Poorly differentiated squamous cell carcinomas	2.74	0.5	2.85×10^2
13	37	male	T1	non cornification undifferentiated carcinoma	2.28	0.13	8.93×10^2
14	43	female	T1	non cornification undifferentiated carcinoma	4.62	4.44	1.11×10^2
15	71	male	T1	non cornification undifferentiated carcinoma	5.51	4.45	1.07×10^3
16	43	male	T1	non cornification undifferentiated carcinoma	0.17	0.75	1.86×10^3
17	50	female	T1	non cornification	3.83	1.44	<5.0×10^2

				undifferentiated carcinoma			
18	56	male	T1	non cornification undifferentiated carcinoma	0.92	0.32	<5.0×10^2
19	39	male	T1	non cornification undifferentiated carcinoma	4.55	2.47	1.33×10^3
20	48	male	T1	non cornification undifferentiated carcinoma	3.77	3.8	1.27×10^3
21	37	male	T1	non cornification undifferentiated carcinoma	4.27	2.94	
22	45	male	T1	non cornification undifferentiated carcinoma	2.12	0.45	1.23×10^3
23	43	male	T1	non cornification undifferentiated carcinoma	3.11	1.01	2.27×10^3
24	50	female	T1	non cornification undifferentiated carcinoma	2.09	0.66	1.03×10^3
25	52	male	T1	non cornification undifferentiated carcinoma	1.11	0.45	1.53×10^2
26	45	male	T4	non cornification undifferentiated carcinoma			7.23×10^2
27	42	male	Т3	non cornification differentiated carcinoma	2.01	0.27	1.53×10^2
28	44	male	Т3	non cornification undifferentiated carcinoma	5.19	4.84	<5.0×10^2
29	36	male	Т2	non cornification undifferentiated carcinoma	3.47	0.33	<5.0×10^2
30	57	female	Т3	non cornification undifferentiated carcinoma	1.82	0.37	5.10×10^2
31	65	male	T4	non cornification undifferentiated carcinoma	0.91	0.22	2.19×10^2
32	38	male	Т2	non cornification undifferentiated carcinoma	2.65	0.1	<5.0×10^2
33	53	female	Т4	non cornification undifferentiated carcinoma	4.79	3.79	9.83×10^3
34	52	male	Т4	cornification squamous cell carcinomas	2.67	2.17	<5.0×10^2
35	52	male	Т2	non cornification undifferentiated carcinoma	5.63	1.7	5.07×10^2
36	56	male	Т4	non cornification undifferentiated carcinoma	2.6	0.73	1.16×10^4
37	40	male	Т2	non cornification undifferentiated carcinoma	6.31	1.78	2.68×10^3
38	62	male	Т2	non cornification undifferentiated carcinoma	3.9	1.2	<5.0×10^2

39	38	male	Т3	non cornification undifferentiated carcinoma	0.65	0.25	1.73×10^3
40	41	male	T4	non cornification undifferentiated carcinoma	1.9	0.15	2.95×10^3
41	36	male	T2	non cornification differentiated carcinoma	4.66	5.13	1.57×10^4
42	61	female	T4	non cornification undifferentiated carcinoma	1.79	0.42	3.71×10^3
43	42	male	T4	Poorly differentiated squamous cell carcinomas	1.09	1	5.0×10^2
44	44	male	T4	non cornification undifferentiated carcinoma	1.54	0.22	1.84×10^3
45	73	female	T4	non cornification undifferentiated carcinoma	3.9	0.13	<5.0×10^2
46	69	male	Т3	Poorly differentiated squamous cell carcinomas	4.96	2.56	<5.0×10^2
47	25	male	T4	non cornification undifferentiated carcinoma	3.8	0.22	<5.0×10^2
48	45	male	Т3	non cornification undifferentiated carcinoma	4.81	5.82	<5.0×10^2
49	47	male	T4	non cornification carcinoma	1.54	5.43	1.15×10^4
50	42	male	T2	non cornification undifferentiated carcinoma	4.37	0.55	1.1×10^3
51	43	male	Т4	non cornification carcinoma	5.48	1.13	<5.0×10^2
52	55	male	T4	non cornification squamous cell carcinomas	1.44	0.41	1.5×10^1
53	39	male	Т2	non cornification undifferentiated carcinoma	2.06	0.49	<5.0×10^2
54	65	male	T4	non cornification undifferentiated carcinoma	2.32	0.76	2.01×10^4
55	40	male	T4	non cornification undifferentiated carcinoma	3.07	2.89	1.16×10^3
56	50	male	Т3	non cornification undifferentiated carcinoma	7.24	5.41	2.47×10^2
57	57	male	Т4	Poorly differentiated squamous cell carcinomas	0.69	0.1	<5.0×10^2
58	42	female	Т4	non cornification undifferentiated carcinoma	5.62	2.27	1.49×10^2
59	35	female	Т3	non cornification undifferentiated carcinoma	7.24	5.4	<5.0×10^2
60	52	female	Т3	non cornification undifferentiated carcinoma	2.35	0.11	2.19×10^4

61	37	male	Т3	non cornification undifferentiated carcinoma	5.33	0.16	1.93×10^4
62	22	female	Т2	non cornification undifferentiated carcinoma	7.24	1.84	1.37×10^2
63	54	male	T4	cornification squamous cell carcinomas	6.28	5.41	2.68×10^4
64	26	male	Т2	non cornification undifferentiated carcinoma	4.86	0.98	3.28×10^3
65	68	female	T4	non cornification undifferentiated carcinoma	5.48	4.05	1.23×10^3
66	59	male	Т2	non cornification carcinoma	4.25	0.58	
67	43	male	Т3	non cornification undifferentiated carcinoma	1.38	0.185	2.01×10^5
68	36	female	Т3	non cornification undifferentiated carcinoma	1.2	0.09	
69	54	male	Т3	non cornification undifferentiated carcinoma	7.25	5.06	1.96×10^3
70	66	male	Т3	non cornification carcinoma	5.01	0.86	3.00×10^3
71	57	male	T4	non cornification undifferentiated carcinoma	5.64	0.76	1.06×10^2
72	34	male	Т2	non cornification undifferentiated carcinoma	5.9	3.24	<5.0×10^2
73	22	male	Т3	non cornification undifferentiated carcinoma			
74	59	male	Т3	non cornification undifferentiated carcinoma	5.91	0.11	7.91×10^2
75	58	male	Т4	non cornification undifferentiated carcinoma	3.05	2.01	<5.0×10^2
76	55	male	Т4	non cornification undifferentiated carcinoma	4.82	2.66	1.12×10^2
77	66	male	Т3	non cornification differentiated carcinoma	1.58	2.89	<5.0×10^2
78	51	male	Т4	non cornification differentiated carcinoma	2.74	3.06	2.40×10^4
79	46	male	Т2	non cornification undifferentiated carcinoma	1.94	0.14	<5.0×10^2
80	37	female	Т2	non cornification undifferentiated carcinoma	4.39	2.88	<5.0×10^2
81	59	male	Т4	Poorly differentiated squamous cell carcinomas	5.81	0.69	1.39×10^2
82	54	female	T4	non cornification undifferentiated carcinoma	3.5	0.23	<5.0×10^2

83	32	male	T2	non cornification undifferentiated carcinoma	4.716	0.255	<5.0×10^2
84	60	male	Т3	non cornification undifferentiated carcinoma	6.47	4.83	<5.0×10^2
85	74	male	Т4	non cornification undifferentiated carcinoma	0.92	0.15	<5.0×10^2
86	57	male	Т3	Poorly differentiated squamous cell carcinomas	3.09	3.84	4.83×10^3
87	39	female	Т3	non cornification undifferentiated carcinoma	4.75	0.57	4.02×10^2
88	65	male	T2	non cornification carcinoma	2.93	0.35	4.27×10^3
89	42	male	T4	non cornification differentiated carcinoma	<0.8	<0.8	<5.0×10^2
90	60	male	Т2	non cornification differentiated carcinoma			8.98×10^2
91	42	female	T4	non cornification differentiated carcinoma	4.23	<0.8	8.54×10^2
92	15	male	T4	non cornification differentiated carcinoma	5.38	4.02	<5.0×10^2
93	59	male	T4	non cornification differentiated carcinoma	2.83	0.47	<5.0×10^2
94	27	male	T2	non cornification differentiated carcinoma	1.49	0.13	<5.0×10^2
95	64	female	T4	non cornification differentiated carcinoma	7.25	3	2.28×10^5
96	43	female	Т3	non cornification undifferentiated carcinoma			
97	34	male	T2	non cornification undifferentiated carcinoma	3.91	3.56	
98	67	male	T2	non cornification undifferentiated carcinoma	3.91	0.67	9.10×10^2
99	43	male	Т3	non cornification undifferentiated carcinoma	1.78	0.16	<5.0×10^2
100	57	male	Т3	non cornification undifferentiated carcinoma	1.6	0.77	8.10×10^2

Table S2. Classification results of blood SERS prediction of the three pathology groups using SERS peak intensity.

Peak (cm ⁻¹)	Diagno	ostic combi	nations	Predicted parameters Sensitivity Specificity AUC		
r cak (cm)	Diagno	ostic comoi	ilations			
492	T1	vs.	N	68%	68.3%	0.757
	T2-T4	vs.	N	65.3%	68.3%	0.738
725	T1	vs.	N	88%	63.3%	0.811
	T2-T4	vs.	N	64%	60%	0.688
1003	T1	vs.	N	88%	85%	0.938
	T2-T4	vs.	N	84%	85%	0.909
1068	T1	vs.	N	64%	61.7%	0.646
	T2-T4	vs.	N	72%	75%	0.790
	T1	vs.	T2-T4	68%	65.3%	0.658
1131	T1	vs.	N	84%	73.3%	0.800
	T2-T4	vs.	N	73.3%	76.7%	0.803
1208	T1	vs.	N	76%	76.7%	0.801
	T2-T4	vs.	N	84%	76.7%	0.862
1402	T2-T4	vs.	N	77.3%	75%	0.839
	T1	vs.	T2-T4	69.3%	72%	0.725
1655	T2-T4	vs.	N	73.3%	81.7%	0.839

T1: Tumor 1 stage nasopharyngeal cancer subject; T2-T4: Tumor 2-4 stage nasopharyngeal cancer subject; N: healthy volunteer subject; AUC: The integration area under the ROC curves.

Table S3 Classification results of blood SERS prediction of samples belonging to one pathology type using PCA-LDA method.

Pathology type	Pro	edicted paramete	ers
	Sensitivity	Specificity	AUC
T1 stage cancer (12 samples vs. 13 samples)	50% (6/12)	30.8% (4/13)	0.558
T2-T4 stage cancer (37 samples vs. 38 samples)	45.9% (17/37)	44.7% (17/38)	0.564
Normal (30 samples vs. 30 samples)	63.3% (19/30)	46.7% (14/30)	0.608

AUC: The integration areas under the ROC curve.

Table S4 Classification results of blood SERS prediction of negative control (rhinitis patients) and previous three pathology groups using PCA-LDA method.

Diagno	stic com	binations	Predicted parameters			
Diagno	suc com	omations	Sensitivity	Specificity	AUC	
Rhinitis	vs.	Normal	30% (3/10)	55% (33/60)	0.604	
Rhinitis	vs.	T1 stage cancer	80% (8/10)	80% (20/25)	0.936	
Rhinitis	vs.	T2-T4 stage cancer	90% (9/10)	92% (69/75)	0.976	

AUC: The integration areas under the ROC curve.